Merrimack

Outthinking Cancer

[Merrimack @MerrimackPharma]

@Eva21164205 hi

[Merrimack @MerrimackPharma]

😄

[Merrimack @MerrimackPharma]

We are taking a systematic approach to our preclinical development work. Learn more about our pipeline here: https://t.co/wwZRfyJQ2f

[Merrimack @MerrimackPharma]

Our pipeline is shaped by understanding cancer pathways, treatments designed with pharmacological properties to match disease need, and clinical strategies with clear rationale. https://t.co/wwZRfyJQ2f

[Merrimack @MerrimackPharma]

October is #BreastCancerAwareness Month. At Merrimack, we stand with everyone who has been affected by this disease and we will continue to work to develop new treatments. #BCAM

[Merrimack @MerrimackPharma]

At Merrimack, innovation is at our core. Want to help us answer the tough questions? Explore our open positions and join our team today: https://t.co/iv4Swr6nWi

[Merrimack @MerrimackPharma]

Meet Daryl Drummond, Ph.D., our Head of Research. Daryl is a principal inventor for many of our nanotechnology-based candidates. https://t.co/W7CcQzGL8X

[Merrimack @MerrimackPharma]

Today we announced the receipt of a $5 million milestone payment from Shire. Read more in the full release: https://t.co/iUuTvZ0Smp

[Merrimack @MerrimackPharma]

Our vision is to see a world where all cancer patients and their families can live fulfilling lives.

[Merrimack @MerrimackPharma]

In case you missed our paper in @scisignal, we recently developed a multi-scale computational model that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. Read more here: https://t.co/1XBIxE7gTZ

[Merrimack @MerrimackPharma]

Today we announced the completion of enrollment in our randomized Phase 2 clinical trial evaluating our lead investigational drug candidate, MM-121, in patients with heregulin positive non-small cell lung cancer. See the full release: https://t.co/4UVWE5565D

[Merrimack @MerrimackPharma]

This week we will be attending Baird's annual Global Health Conference. Tune in to the webcast on September 6 at 8:25 a.m.: https://t.co/vKfGKvM4T1

[Merrimack @MerrimackPharma]

Innovation doesn't happen alone. Learn more about collaborating with us: https://t.co/qD4VuAeI0f

[Merrimack @MerrimackPharma]

Innovation is at our core and we've built our culture on cooperation and collaboration. Learn more about our team and explore open career opportunities: https://t.co/OxT57TOfRP

[Merrimack @MerrimackPharma]

A cornerstone of our development strategy is to establish efficacy through clinical studies in biomarker-enriched patient populations. Learn more about our ongoing studies:Ê https://t.co/6zPFtZNtOE

[Merrimack @MerrimackPharma]

We're developing a new generation of treatments for #cancer through a focused pipeline of precise, targeted therapies. Discover more: https://t.co/9H51iikmHB

[Merrimack @MerrimackPharma]

Our team cares deeply about our mission and is driven by a desire to improve the lives of patients. https://t.co/9H51iikmHB

[Merrimack @MerrimackPharma]

Check out our paper in @scisignal exploring a multi-scale computational model we developed that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. https://t.co/TmIr7PXiHR

[Merrimack @MerrimackPharma]

Our programs are backed by our systems biology expertise and a clear clinical rationale. Explore our published research and presentations: https://t.co/9H51iikmHB

[Science Signaling @scisignal]

Computational modeling predicts how cancer cells respond to combinations of #chemotherapy and #DNArepair inhibitors @MerrimackPharma @MIT